Zymeworks and alx oncology announce first patient dosed in phase 1b/2 clinical trial of zanidatamab and evorpacept (alx148) in patients with advanced her2-expressing breast cancer and other solid tumors

Vancouver, british columbia & south san francisco, calif.--(business wire)--zymeworks inc. (nyse: zyme), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, and alx oncology holdings inc. (nasdaq: alxo), a clinical-stage immuno-oncology company developing therapies that block the cd47 checkpoint pathway, today announced the first patient has been dosed in an open-label, multi-center phase 1b/2 clinical trial conducted by zymeworks. the trial is designed to eva
ALXO Ratings Summary
ALXO Quant Ranking